Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and Sustainability
In this sponsored GEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The post Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate…
In the GEN Podcast – the second installment of a three-part series – industry experts from SK Pharmtech discuss the growing role of contract development and manufacturing organizations (CDMOs) in assisting pharmaceutical sponsors. These CDMOs are helping to tackle a range of challenges that have emerged due to increased molecular complexity, shorter development timelines, and evolving manufacturing and regulatory needs.
The experts explore key areas where CDMOs are making an impact, including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the integration of artificial intelligence (AI), and ensuring supply chain reliability. The conversation focuses on practical approaches to enhance development efficiency while maintaining quality, scalability, and long-term commercial success.
The podcast's guests include Steve Barr, PhD, Head of Small Molecule Business Unit and VP of Global Alliances at SK Pharmtech; Darryl Ratty, Executive Director of Global ESG at SK Pharmtech; and Bill DuBay, Vice President of Global Research and Development at SK Pharmtech. The discussion is sponsored by The GEN Podcast.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
